AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Net Income

Bottom-line profit, the starting point for calculating cash from operations.

AC Immune S.A.NASDAQ: ACIU

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income dips below year-ago levels

Q4 FY2025 net income of CHF 14.26M (cash outflow) fell 9.7% year over year, behind the +38.1% change in trailing-twelve-month net income. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Net income amounted to 1883.0% of revenue in FY2025, up 1696.6 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -CHF 40.1M (-40.4%) for the fiscal year ending Dec 2026, a slowdown from the +32.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 14.26M-10.1% QoQ
Last fiscal yearDec 2025
-CHF 67.28M+32.1% YoY
LTMDec 2025
-CHF 70.34M+38.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.7%-20.6%-10.9 pp
1 year+32.1%-40.4%-72.5 pp
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CHF · from the cash flow

Latest · FY2025
(67.28M) CHF
Year-over-year change
-32.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +38.1% is the 2nd highest of 10, against a peer median of +17.3%.
  • Net income amounts to 1968.6% of revenue for ACIU, versus a peer median of 7142.0%.
ACIU Competitors
Net Income for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
ANNXAnnexon, Inc.LTM Mar 2026$196.48M USD+17.4%+13.3%—
SLNSilence Therapeutics plcLTM Mar 2026$145.44M USD—+20.7%15782.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M USD+17.6%+31.7%—
ACIUAC Immune S.A.LTM Dec 2025CHF 70.34M CHF+38.1%-1.7%1968.6%
CLLSCellectis S.A.LTM Mar 2026$67.27M USD+11.1%-11.8%98.8%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$58.44M USD+17.3%+35.2%—
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$42.63M USD+34.3%+8.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$35.71M USD-24.3%-0.3%7142.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$27.37M USD-52.6%-18.3%—
AMRNAmarin Corporation plcLTM Mar 2026$5.23M USD+106.0%-28.4%2.4%
Peer median (excluding ACIU) —+17.3%+10.7%7142.0%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.